The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis
Open accessAbstract
BACKGROUND: Cyclophosphamide and glucocorticoids have been the cornerstone of remission-induction therapy for severe antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis for 40 years. Uncontrolled studies suggest that rituximab is effective and may be safer than a cyclophosphamide-based regimen. METHODS: We conducted a multicenter, randomized, double-blind, double-dummy, noninferiority trial of rituximab (375 mg per square meter of body-surface area per week for 4 weeks) as compared with cyclophosphamide (2 mg per kilogram of body weight per day) for remission induction. Glucocorticoids were tapered off; the primary end point was remission of disease without the use of prednisone at 6 months. RESULTS: Nine centers enrolled 197 ANCA-positive patients with either Wegener's granulomatosis or microscopic polyangiitis. Baseline disease activity, organ involvement, and the proportion of patients with relapsing disease were similar in the two treatment groups. Sixty-three patients in the rituximab group (64%) reached the primary end point, as compared with 52 patients in the control group (53%), a result that met the criterion for noninferiority (P<0.001). The rituximab-based regimen was more efficacious than the cyclophosphamide-based regimen for inducing remission of relapsing disease; 34 of 51 patients in the rituximab group (67%) as compared with 21 of 50 patients in the control group (42%) reached the primary end point (P=0.01). Rituximab was also as effective as cyclophosphamide in the treatment of patients with major renal disease or alveolar hemorrhage. There were no significant differences between the treatment groups with respect to rates of adverse events. CONCLUSIONS: Rituximab therapy was not inferior to daily cyclophosphamide treatment for induction of remission in severe ANCA-associated vasculitis and may be superior in relapsing disease. (Funded by the National Institutes of Allergy and Infectious Diseases, Genentech, and Biogen; ClinicalTrials.gov number, NCT00104299.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nomenclature of Systemic Vasculitides
Jennette, J. C., Falk, R. J., Andrassy, K., Bacon, P. A., Churg, J., Gross, W. L., Hagen, E. C., Hoffman, G. S., Hunder, G. G., Kallenberg, C. G. M., et al. (1994) · Arthritis & Rheumatism · doi:10.1002/art.1780370206 · Cited by 3,845
Self-citationWegener Granulomatosis: An Analysis of 158 Patients
Hoffman, G. S., Kerr, G. S., Leavitt, R. Y., Hallahan, C. W., Lebovics, R. S., Travis, W. D., Rottem, M., & Fauci, A. S. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-116-6-488 · Cited by 2,857
Self-citationOverview of the SF-36 Health Survey and the International Quality of Life Assessment (IQOLA) Project
Ware, J. E., & Gandek, B. (1998) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(98)00081-x · Cited by 2,605
FAUCI, A. S., HAYNES, B. F., KATZ, P., & WOLFF, S. M. (1983) · Annals of Internal Medicine · doi:10.7326/0003-4819-98-1-76 · Cited by 2,001
Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis
Jones, R. B., Cohen Tervaert, J. W., Hauser, T., Luqmani, R., Morgan, M. D., Peh, C. A., Savage, C. O., Segelmark, M., Tesar, V., van Paassen, P., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909169 · Cited by 1,748
Statistics in Medicine — Reporting of Subgroup Analyses in Clinical Trials
Wang, R., Lagakos, S. W., Ware, J. H., Hunter, D. J., & Drazen, J. M. (2007) · New England Journal of Medicine · doi:10.1056/nejmsr077003 · Cited by 1,445
Jayne, D., Rasmussen, N., Andrassy, K., Bacon, P., Tervaert, J. W. C., Dadoniené, J., Ekstrand, A., Gaskin, G., Gregorini, G., de Groot, K., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020286 · Cited by 1,348
de Groot, K., Harper, L., Jayne, D. R. W., Flores Suarez, L. F., Gregorini, G., Gross, W. L., Luqmani, R., Pusey, C. D., Rasmussen, N., Sinico, R. A., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-10-200905190-00004 · Cited by 957
Giant-cell Granuloma of the Respiratory Tract (Wegener's Granulomatosis)
Walton, E. W. (1958) · BMJ · doi:10.1136/bmj.2.5091.265 · Cited by 930
Etanercept plus Standard Therapy for Wegener's Granulomatosis
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa041884 · Cited by 834
Cited by
RETRACTED: Avacopan for the Treatment of ANCA-Associated Vasculitis
Jayne, D. R. W., Merkel, P. A., Schall, T. J., & Bekker, P. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2023386 · Cited by 1,021
Self-citationRetractedGroh, M., Pagnoux, C., Baldini, C., Bel, E., Bottero, P., Cottin, V., Dalhoff, K., Dunogué, B., Gross, W., Holle, J., et al. (2015) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2015.04.022 · Cited by 476
Self-citationAltered B cell signalling in autoimmunity
Rawlings, D. J., Metzler, G., Wray-Dutra, M., & Jackson, S. W. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2017.24 · Cited by 308
Rituximab in severe, treatment-refractory interstitial lung disease
Keir, G. J., Maher, T. M., Ming, D., Abdullah, R., de Lauretis, A., Wickremasinghe, M., Nicholson, A. G., Hansell, D. M., Wells, A. U., & Renzoni, E. A. (2014) · Respirology · doi:10.1111/resp.12214 · Cited by 256
Smith, R. M., Jones, R. B., Guerry, M., Laurino, S., Catapano, F., Chaudhry, A., Smith, K. G. C., & Jayne, D. R. W. (2012) · Arthritis & Rheumatism · doi:10.1002/art.34583 · Cited by 250
Metadata
- Authors
- Stone, J. H., Merkel, P. A., Spiera, R., Seo, P., Langford, C. A., Hoffman, G. S., Kallenberg, C. G. M., St. Clair, E. W., Turkiewicz, A., Tchao, N. K., Webber, L., Ding, L., Sejismundo, L. P., Mieras, K., Weitzenkamp, D., Ikle, D., Seyfert-Margolis, V., Mueller, M., Brunetta, P., Allen, N. B., Fervenza, F. C., Geetha, D., Keogh, K. A., Kissin, E. Y., Monach, P. A., Peikert, T., Stegeman, C., Ytterberg, S. R., & Specks, U.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2010-07-15
- Volume
- 363
- Issue
- 3
- Pages
- 221-232
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2063340779
- Cited by
- 2,762
- References
- 29
- FWCI
- 124.95
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis. https://app.cochat.ai/papers/10.1056/nejmoa0909905
- The paper
- Stone, J. H., Merkel, P. A., Spiera, R., Seo, P., Langford, C. A., Hoffman, G. S., Kallenberg, C. G. M., St. Clair, E. W., Turkiewicz, A., Tchao, N. K., Webber, L., Ding, L., Sejismundo, L. P., Mieras, K., Weitzenkamp, D., Ikle, D., Seyfert-Margolis, V., Mueller, M., Brunetta, P., . . . Specks, U. (2010). Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis. New England Journal of Medicine. https://doi.org/10.1056/nejmoa0909905
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
